Avrobio is stopping enrollment in a clinical trial for its Fabry disease program after new results showed variability in how the gene therapy was taken up by patients. No safety problems were reported, but the biotech said it now plans to focus its other gene therapy candidates for rare metabolic disorders.
Avrobio has secured $60 million in new financing on the back of its first successful gene therapy trial in a patient with Fabry disease.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
AvroBio's lentiviral gene therapy approach works by infusing genetically modified cells into a patient.